Tag:
Abraxane
Latest Headlines
Latest Headlines
Celgene gets disappointing Abraxane data
After lifting its earnings projections three times in 2010, Celgene ( $CELG ) is now saying fourth-quarter numbers will miss the mark. But the real disappointment was Abraxane, the drug Celgene bought
Abraxis deal done, Celgene eyes cancer franchise
Now that Celgene has wrapped up its $3 billion-plus buyout of Abraxis BioScience, analysts are cheering. That wasn't necessarily the case in June, when the companies announced their deal--and
Celgene moves into solid tumors with Abraxis buy
When Celgene ( NASDAQ: CELG ) buys Abraxis BioScience ( NASDAQ: ABII ) for up to $3.55 billion, it will move into a vein of cancer therapy that it's never mined before. On its own, Celgene markets some
ASCO spotlights new tricks for existing drugs
Much of the focus at the annual American Society of Clinical Oncology meeting is on experimental meds: What pipeline remedies are proving most effective for the companies testing them? But existing
Abraxis spins off personalized medicine company
Abraxis BioScience is spinning off Abraxis Health, creating a standalone company that will operate in the personalized medicine arena. "The opportunity that lies in front of Abraxis BioScience is
Abraxis would pay $268M to get Abraxane back
Call it a case of hindsight. Abraxis Bioscience and AstraZeneca are poised to end their two-year marketing partnership on the breast cancer treatment Abraxane, which cost Astra $200 million back in
Costs put cancer docs in financial bind
Pricey cancer meds aren't just putting the squeeze on patients and insurers. They're putting oncologists in a financial quandary as well. We got an inkling of this recently when the American Society
Elan wins $55M judgment in patent scrap
Ireland's Elan won a $55.2 million judgment against Abraxis BioScience on Friday, prevailing in its case that Abraxis' breast cancer drug Abraxane uses a technology protected by an Elan patent.
AstraZeneca, Abraxis ink $200M licensing pact
AstraZeneca and Abraxis BioScience have wrapped a deal to share the promotional rights to the cancer drug Abraxane in the U.S. Abraxane is currently approved for breast cancer but is being developed
